

2 July 2020

ASX ANNOUNCEMENT

ANTERIS OPERATIONS UPDATE

Anteris Technologies (ASX:AVR) continues to meet its operations schedule despite the impact of COVID-19 global restrictions. Countermeasures the Company adopted early in the pandemic have ensured the safety and well-being of staff without significantly compromising operations.

The greatest impact remains on travel restrictions to medical conferences and face-to-face meetings with potential partners important to promoting the Company's TAVR development programme.

Notwithstanding these impediments, Anteris is committed to concluding partnership deals for TAVR development this year as outlined in its FY19 Annual Report.

Also, in 2020, Anteris aims to conclude partnership deals for supply of ADAPT[®] tissue. Product innovation continues, led by the TAVR programme. Other large market opportunities are at varying stages of design development, regulatory clearance and user evaluation. In manufacturing, the Company is continually improving efficiency to reduce costs and maximise margins and yields.

Specifically, regarding its 2020 objectives, Anteris commenced:

- ✓ in March, its 15 patient clinical study of its DurAVR[™] valve in surgical aorta valve replacement (SAVR). The Federal Agency for Medicines and Health Products (FAMHP) of Belgium granted approval to conduct the first-in-human study on 11 March 2020;
- ✓ in May, its preclinical study comparing anti-calcification properties of its proprietary ADAPT[®] treated tissue with other bovine and porcine tissues used in commercially available SAVR and TAVR valves. Calcification plays a significant role in the failure of bioprosthetic and other tissue heart valve substitutes; and

Anteris Technologies Ltd


Registered Office:

Suite 302, Level 3 Toowong Tower, 9 Sherwood Road, Toowong QLD 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@anteristech.com W: anteristech.com



- ✓ in June, the feasibility study in three pigs of its proprietary DurAVR™ Transcatheter Heart Valve as part of a transcatheter aortic valve replacement (TAVR) study in a porcine model to be completed by year end.

The Company, also, completed:

- ✓ in February, the transfer of its unique Sterilisation Method (as part of its ADAPT® tissue treatment process) to 4C Medical Technologies, Inc for an additional \$US1 Million (\$US0.44M previously received) to use the technology to sterilise the ADAPT® tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValve™ system device; and
- ✓ in March, the consolidation of its issued capital as part of the Company's restructuring and recapitalisation plan.

"That Anteris has delivered on its goals, on time, amidst this terrible pandemic is a tribute to the dedication and efforts of staff, consultants and contractors sharing the Company's vision. We trust success begets success for the year remaining. Barring unforeseen events, I expect Anteris will end the year achieving all milestones set for 2020," Wayne Paterson, Anteris Chief Executive Officer, said.

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Managing Director.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 401 018 828

www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech

